Member Info for flava

Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, announces that Sara Barrington, CEO, will provide a live presentation relating to the Company's recent global licensing and commercialisation agreement for its pre-transplant test (Clarava?) with Thermo Fisher Scientific (https://verici-dx-plc.flint-platform.com/regulatory-news/44270), via the Investor Meet Company platform on 22 November 2023 at 17.00 (GMT).

The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9am the day before the meeting or at any time during the live presentation.

Investors can sign up to Investor Meet Company for free and add to meet VERICI DX PLC via:

https://www.investormeetcompany.com/verici-dx-plc/register-investor

Verici Dx signs exclusive global licensing agreement with Thermo Fisher Scientific for pre-transplant prognostic testing

Key highlights:

✅Verici Dx has granted Thermo Fisher Scientific an exclusive global license to further develop an assay for pre-transplant risk assessment for early kidney rejection.

✅The agreement includes an upfront payment of $5 million, along with ongoing royalties on tests sold.

✅Thermo Fisher Scientific will also have non-exclusive access to a portion of Verici Dx's urine biorepository.

Impact:

✅The agreement is expected to accelerate the development of Verici Dx's technology and help it reach more patients.

✅The collaboration will expand Thermo Fisher Scientific's portfolio of transplant testing solutions.

✅This is a positive development for kidney transplant patients, as it could lead to earlier diagnosis and treatment of organ rejection.

Tr1 maybe in coming weeks.

Finally, the big seller is out, and we should move upwards slowly but surely now. A 30p target for starters and a 50p target by the end of this year seem reasonable.

1,455,240 trade from Wednesday and £38k buy.

Unicorn Asset Management increased their holding by 2% at 34p in March last year. I'm guessing someone is loading up big time here and MMs are dropping the price to fill large orders.

Unicorn Asset Management Ltd. - 5.425% (9,239,660 shares)

Canaccord Genuity Wealth Ltd. - 4.247% (7,233,697 shares)

AXA Investment Managers UK Ltd. - 2.237% (3,809,580 shares)

Schroder Investment Management Ltd. - 1.294% (2,216,632 shares)

EKF Diagnostics Holdings PLC - 1.223% (2,092,797 shares)

Other institutional investors - 16.456% (28,043,383 shares)

Retail investors - 68.655% (116,076,280 shares)

Maybe no one is pumping the stock via Twitter and posting nonstop about it here. :)

Just fill your boots, this will motor very soon.

Yes, Verici Dx is currently undervalued and not yet on the radar of big investors.

According to Verici Dx CEO Sara Barrington, the company is valued much higher for insurance purposes in order to meet certain requirements before the JV deal with Thermo Fisher. She is not saying much about what the company should be worth after this deal, but some has suggested a range of 40p to 50p.

https://www.voxmarkets.co.uk/articles/q-a-wit-verici-dx-ceo-sara-barrington-0087adb/

Thermo Fisher Scientific Inc., with a market cap of 182 billion USD, partnering with Verici Dx is indeed very big news.

Many investors do not realise the significance of this joint venture deal.

This reminds me of #POS Plexus stock when they received contract news. It moved nearly 650% from 2.50p to 20p.

Just slowly build your stake here and watch your investment flourish very soon.

Give it a rest, non-stop running commentary :) You should get a job commenting on football matches, lol.

This reminds me of #POS Plexus stock when they received contract news. It moved nearly 650% from 2.50p to 20p.

Just slowly build your stake here and watch your investment flourish very soon.

Nice big chuck of buys at £14,600 paid 11.42p

08:19:36 11.4229 127,813 14.60k

11p need to break then touch mid 18-20p very soon.

Placing at 35 pence per share last year. Multibagger!

This dropped from 72p in November 2021, marking a massive turnaround now. An easy 25p valuation is achievable after today's news.

What's the target price here after the mega RNS this morning?

Let's see if your right Petro :)

......................